RCS - SynBiotic SE - SynBiotic SE attracts Canopy Growth founder
24/11/2022 12:30
For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20221124:nRSX5193Ha&default-theme=true
RNS Number : 5193H SynBiotic SE 24 November 2022
SynBiotic SE / Key word(s): Personnel
SynBiotic SE attracts Canopy Growth founder Bruce Linton as Chairman of newly
created Advisory Board
24.11.2022 / 10:13 CET/CEST
The issuer is solely responsible for the content of this announcement.
SynBiotic SE attracts Canopy Growth founder Bruce Linton as Chairman of newly
created Advisory Board
Munich, 24th November 2022:
SynBiotic SE, (SBX.DE) one of Germany's leading cannabinoid companies,
accelerates implementation of the operational platform to achieve market
leadership in the upcoming national legalization of recreational cannabis by
securing Bruce Linton to its team.
Mr. Linton is one of the most experienced and most successful cannabis
entrepreneurs and investors globally and has been the driving force behind the
creation of multiple global multi-billion dollar cannabis enterprises, several
of them listed on NYSE, Nasdaq, TSX, TSX:V, CSE and ASX.
Most notably, Mr. Linton is the founder and former Chairman and CEO of the
global cannabis company Canopy Growth Corporation, which, at the time of his
departure, had a market valuation of approximately CAD 20 billion and more
than 25% market share in the Canadian recreational market while also being a
global top tier supplier. Canopy was the first North American supplier to the
German medical cannabis market. Combining unparalleled expertise in the areas
of both medical and recreational cannabis, Mr Linton is a powerful asset given
SynBiotic's expansion plans, which cover both segments.
Mr. Linton has been appointed as Chairman of SynBiotic's newly created
Advisory Board and has invested capital in the company's most recent financing
round. His investment plus options to buy further shares from existing
shareholders will bring him to an ownership of approx. 5% in SynBiotic.
He will draw no fixed cash salary and will be remunerated based on share price
performance and other operational milestones, giving him full alignment with
shareholders.
Mr. Linton stated "I see enormous potential in the European market,
particularly in Germany because of the recently announced legalization in
Europe's largest economy. I regard SynBiotic as best positioned to take full
advantage of the legalization and become Europe's dominant cannabis company. I
am very much looking forward to being part of this success story and to
working with the amazing team around founder Lars Müller."
Lars Müller, CEO of SynBiotic SE, states: "The fact that we are working with
Bruce Linton is a true accolade. With the forthcoming legalization of
recreational cannabis in Germany, SynBiotic SE will benefit massively from the
know-how of one of the global industry pioneers. His faith in SynBiotic SE is
a great honor for me and shows us that we are on the right track with our
vision."
About SynBiotic SE
SynBiotic SE is the largest listed group of companies in Europe in the hemp
and cannabis sector and pursues a buy-&-build investment strategy focused
across the European Union. The group of companies covers the entire supply
chain from cultivation through production to retail - from field to shelf. A
core business of the company is the research & development, production and
marketing of cannabinoid and terpene-based solutions to address major societal
problems such as pain, sleep deprivation and anxiety. In addition to the food
supplement and cosmetics market, SynBiotic SE is also active in the medical
sector, and will shortly also enter the recreational cannabis sector.
24.11.2022 CET/CEST Dissemination of a Corporate News, transmitted by EQS News
- a service of EQS Group AG.
The issuer is solely responsible for the content of this announcement.
The EQS Distribution Services include Regulatory Announcements,
Financial/Corporate News and Press Releases.
Archive at www.eqs-news.com
Language: English
Company: SynBiotic SE
Barer Str. 7
80333 München
Germany
E-mail: office@synbiotic.com
Internet: https://www.synbiotic.com/
ISIN: DE000A3E5A59
WKN: A3E5A5
Listed: Regulated Unofficial Market in Berlin, Dusseldorf, Frankfurt, Munich,
Tradegate Exchange
EQS News ID: 1495559
End of News EQS News Service
1495559 24.11.2022 CET/CEST
This information is provided by Reach, the non-regulatory press release distribution service of RNS, part of the London Stock Exchange. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
or visit
www.rns.com (http://www.rns.com/)
.
Reach is a non-regulatory news service. By using this service an issuer is confirming that the information contained within this announcement is of a non-regulatory nature. Reach announcements are identified with an orange label and the word “Reach” in the source column of the News Explorer pages of London Stock Exchange’s website so that they are distinguished from the RNS UK regulatory service. Other vendors subscribing for Reach press releases may use a different method to distinguish Reach announcements from UK regulatory news.
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
. END NRAFZLFLLFLLFBB